Table 1.
Elevated (>99 percentile) hs-troponin T by Rochea | Elevated (>99 percentile) hs-troponin I by Abbotta | Elevated (>99 percentile) hs-troponin I by Siemensa | Elevated (>99 percentile) hs-troponin I by Orthoa | |
---|---|---|---|---|
Total, % | 3.11 | 0.60 | 0.93 | 0.75 |
Gender, % | ||||
Male | 2.54 | 0.52 | 1.02 | 0.66 |
Female | 3.62 | 0.67 | 0.85 | 0.82 |
Age categories, % | ||||
18–39 years | 0.33 | 0.36 | 0.41 | 0.32 |
40–59 years | 1.74 | 0.38 | 0.70 | 0.48 |
60 years or older | 12.6 | 1.64 | 2.64 | 2.32 |
Race/ethnicity, % | ||||
NH White | 3.34 | 0.55 | 0.81 | 0.74 |
NH Black | 4.35 | 1.48 | 1.71 | 1.50 |
Mexican–American | 1.19 | 0.43 | 0.88 | 0.22 |
Other/other Hispanic | 1.66 | 0.16 | 1.00 | 0.41 |
Hypertension, % | ||||
No | 1.51 | 0.37 | 0.60 | 0.44 |
Yes | 7.70 | 1.21 | 1.82 | 1.57 |
Hypercholesterolemia, % | ||||
No | 2.49 | 0.51 | 0.79 | 0.65 |
Yes | 5.15 | 0.89 | 1.40 | 1.05 |
eGFR, mL/min/1.73 m2, % | ||||
>90 | 1.84 | 0.34 | 0.57 | 0.36 |
60–90 | 21.3 | 0.96 | 2.36 | 1.28 |
<60 | 65.3 | 7.86 | 5.35 | 11.4 |
Smoking status, % | ||||
Current | 2.08 | 0.49 | 0.62 | 0.43 |
Former | 4.75 | 0.77 | 1.38 | 1.37 |
Never | 2.84 | 0.57 | 0.87 | 0.61 |
Family history of CVD, % | ||||
No | 3.32 | 0.64 | 1.02 | 0.79 |
Yes | 1.83 | 0.36 | 0.36 | 0.50 |
Diabetes mellitus, % | ||||
No | 2.73 | 0.55 | 0.88 | 0.74 |
Yes | 10.1 | 1.55 | 1.97 | 0.91 |
BMI, kg/m2, % | ||||
<25 | 3.36 | 0.63 | 0.98 | 0.72 |
25–30 | 2.87 | 0.53 | 0.99 | 0.85 |
>30 | 3.10 | 0.64 | 0.81 | 0.65 |
BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration ratio using the creatinine cystatin equation; HDL, high-density lipoprotein; NH, non-Hispanic; SBP, systolic blood pressure; URL, upper reference limit.
Values above the manufacturer-designated assay- and sex-specific 99th percentile URL myocardial injury threshold were defined as elevated; troponin T 14(f)/22(m) ng/L; troponin I, Abbott 17(f)/35(m) ng/L; troponin I, Siemens 39.6(f)/58(m) ng/L; troponin I, Ortho 9(f) 12(m) ng/L.